Introduction
============

The global incidence and mortality rates of gastric cancer (GC) are amongst the highest for all malignant tumor types ([@b1-ol-0-0-5881]). Risk factors that may increase an individual\'s chance of developing GC include *Helicobacter pylori* infection, a diet high in salty/smoked food and low in fruit/vegetables, tobacco smoking and genetic susceptibility ([@b2-ol-0-0-5881]). Additionally, the incidence rate of GC is \~2 times higher in males compared with females, independently of known gender-specific variables ([@b3-ol-0-0-5881]). Therefore, it has been proposed that steroid hormone production influences the risk of developing GC ([@b4-ol-0-0-5881],[@b5-ol-0-0-5881]). Furthermore, numerous studies have suggested a protective role of 17β-estradiol (E2) in gastric carcinogenesis ([@b6-ol-0-0-5881]--[@b12-ol-0-0-5881]). Although the majority of E2 is produced in the ovaries, it is also synthesized locally in peripheral tissues in males and females ([@b13-ol-0-0-5881]).

There are two routes involved in the local synthesis of E2, the sulfatase and aromatase signaling pathways ([@b13-ol-0-0-5881]). The sulfatase signaling pathway involves the desulfation of dehydroepiandrosterone sulfate (DHEA-S) and estrone sulfate (E1-S) to DHEA and E1, respectively, by steroid sulfatase (STS). Subsequently, E1 is reduced to E2 by 17β-hydroxysteroid dehydrogenases (HSD17Bs; types 1, 5 and 7). In addition, DHEA is converted to androstenedione (adione) by hydroxy-delta-5-steroid dehydrogenase 3 beta- and steroid delta-isomerase 1 (HSD3B1). In the aromatase signaling pathway, adione and testosterone are converted into E1 and E2, respectively, by aromatase (CYP19A1) ([@b14-ol-0-0-5881]). In recent studies, the mRNA and protein expression of enzymes belonging to the HSD17B family, including HSD17B1, 2 and 5 was demonstrated in healthy and tumoral gastric mucosa ([@b15-ol-0-0-5881]--[@b17-ol-0-0-5881]). In addition, it was revealed that the HGC-27 and EPG 85--257 GC cell lines were able to synthesize E2 *in vitro* ([@b15-ol-0-0-5881]).

In the present study, the mRNA levels of certain genes that participate in the synthesis of E2 through the sulfatase and aromatase signaling pathways, including STS, HSD3B1, CYP19A1 and HSD17B7, were investigated in primary tumoral and healthy adjacent gastric mucosa samples from patients with GC. Furthermore, considering the fact that the cellular functions of steroid hormones are mediated through binding to their receptors and that the abnormal expression of genes encoding nuclear estrogen receptors α (ESR1) and β (ESR2), and androgen receptor (AR) have been demonstrated in GC ([@b18-ol-0-0-5881],[@b19-ol-0-0-5881]), the mRNA expression of coactivators and corepressors of steroid hormone receptors were also determined in the tissue samples. The following coactivators and corepressors were investigated: Proline, glutamate and leucine rich protein 1 (PELP1); CREB binding protein (CREBBP); nuclear receptor coactivator 1 (NCOA1); nuclear receptor corepressor 1 (NCOR1); and nuclear receptor subfamily 2, group F, member 1 (NR2F1). Additionally, the association between the mRNA expression of the genes investigated and the clinicopathological features of patients with GC was investigated.

Materials and methods
=====================

### Patients and tissue specimens

Primary tumoral gastric mucosa specimens were collected between December 2012 and September 2015 from 60 patients with a mean age of 67.2 years old who underwent a total gastrectomy at the First Department of Surgical Oncology and General Surgery at the Greater Poland Cancer Centre or the Department of General and Endocrine Surgery and Gastroenterological Oncology, Heliodor Święcicki Clinical Hospital at the Poznań University of Medical Sciences (Poznań, Poland). The clinicopathological characteristics of the patients are presented in [Table I](#tI-ol-0-0-5881){ref-type="table"}; however, for certain patients not all the information was available. In addition, healthy gastric mucosa tissue samples located ≥10 cm away from the tumoral lesions was obtained from each patient. Specimens were snap-frozen in liquid nitrogen and stored at −80°C until required for RNA isolation. An experienced pathologist performed histopathological assessments of the tissue samples ([Table I](#tI-ol-0-0-5881){ref-type="table"}). The present study was approved by the Ethics Committee of Poznań University of Medical Sciences. Written informed consent was obtained from all patients.

### Reverse transcription-quantitative polymerase chain reaction analysis

Total RNA from patient tissue samples was isolated according to Chomczynski and Sacchi\'s single-step method ([@b20-ol-0-0-5881]), which involves homogenization. The concentration and integrity of the RNA isolated was assessed using a Nano-100 Micro Spectrophotometer (Hangzhou Allsheng Instruments Co., Ltd., Hangzhou, China) and non-denaturing electrophoresis on a 1.5% agarose gel, respectively. RNA samples were treated with DNase I and reverse-transcribed into cDNA using a SuperScript^®^ III First-Strand Synthesis system (Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer\'s protocol, using 1 µg of RNA as a template.

The target cDNA was quantified by the relative quantification method using a calibrator, as is described in the Relative Quantification Manual (Roche Diagnostics GmbH, Mannheim, Germany) ([@b21-ol-0-0-5881]). The calibrator was prepared as a cDNA mix from all of the patient samples and its successive dilutions were used to create a standard curve. qPCR reactions were performed using a LightCycler^®^ 480 Real-Time PCR system (Roche Diagnostics GmbH, Mannheim, Germany). Each qPCR reaction contained 1 µl of total cDNA solution obtained in reverse transcription, 9 µl LightCycler 480 SYBR Green I Master mix (Roche Diagnostics GmbH) and 0.1 µM of the corresponding primer pair ([Table II](#tII-ol-0-0-5881){ref-type="table"}). Primers for ESR1, ESR2 and HSD17B7 were purchased from Sigma-Aldrich (Merck Millipore, Darmstadt, Germany) and the β2-microglobulin (B2M) primers were previously designed by Hashimoto *et al* ([@b22-ol-0-0-5881]). The primers for CYP19A1 were designed using the Universal ProbeLibrary website (Roche Diagnostics GmbH). All other primers were designed using OLIGO Primer Analysis Software (version 5.0; Molecular Biology Insights, Inc., Colorado Springs, CO, USA). qPCR thermocycling conditions consisted of a pre-denaturation step at 95°C for 7 min followed by 42 PCR cycles specific for each primer. Reaction conditions for each primer pair are detailed in [Table II](#tII-ol-0-0-5881){ref-type="table"}. The analyzed transcript levels were expressed as the ratio between the amount of target transcript in a sample and target transcript in the calibrator. The quantity of analyzed transcripts in each sample was standardized by the geometric mean of B2M, β-glucuronidase and porphobilinogen deaminase, and presented as the decimal logarithm.

### Statistical analysis

Normality of data distribution was assessed using the Shapiro-Wilk test, followed by a Student\'s t-test (two-tailed) or Mann-Whitney U test to determine significant differences between mean values. P\<0.01 was considered to indicate a statistically significant difference. STATISTICA software (version 10; StatSoft, Inc., Tulsa, OK, USA) was used to perform all statistical analyses.

Results
=======

### mRNA expression of STS, HSD3B1, CYP19A1, HSD17B7, ESR1, ESR2, AR, PELP1, CREBBP, NCOA1, NCOR1 and NR2F1 in primary tumoral and healthy gastric mucosa of patients with GC

RT-qPCR was used to measure the mRNA expression of genes encoding steroidogenic enzymes (STS, CYP19A1, HSD3B1, HSD17B7), steroid hormone receptors (ESR1, ESR2, AR) and coregulators of steroid hormone receptors (PELP1, CREBBP, NCOA1, NCOR1, NR2F1), in primary tumoral and adjacent healthy mucosa tissue samples from 60 patients with GC ([Fig. 1](#f1-ol-0-0-5881){ref-type="fig"}). Expression of STS and HSD17B7 mRNA was detected in all tissue samples examined, whereas expression of HSD3B1 mRNA was absent in one healthy tissue sample and CYP19A1 was not detected in seven healthy specimens ([Fig. 1A](#f1-ol-0-0-5881){ref-type="fig"}). Furthermore, five cancerous tissue samples demonstrated no expression of HSD3B1 mRNA. There was no difference in the mRNA level of HSD17B7 in primary tumoral and adjacent healthy mucosa (P=0.2; [Fig. 1A](#f1-ol-0-0-5881){ref-type="fig"}). However, significantly lower mRNA levels of STS (P\<0.00001) and HSD3B1 (P=0.0051) were identified in tumoral tissue samples compared with healthy tissue samples. Tumoral tissue samples revealed a significantly increased expression of CYP19A1 mRNA compared with control samples (P\<0.00001; [Fig. 1A](#f1-ol-0-0-5881){ref-type="fig"}). However, despite the significant differences observed, HSD3B1 and CYP19A1 mRNA levels were maintained at low levels in primary tumoral and healthy gastric mucosa compared with STS and HSD17B7 mRNA (data not shown).

mRNA of the investigated steroid hormone receptors ([Fig. 1B](#f1-ol-0-0-5881){ref-type="fig"}) and their coregulators ([Fig. 1C](#f1-ol-0-0-5881){ref-type="fig"}) was detected in all 60 pairs of gastric tumor and adjacent healthy control samples. No significant difference was observed in the expression of ESR1 mRNA between primary tumoral and adjacent healthy mucosa (P=0.26; [Fig. 1B](#f1-ol-0-0-5881){ref-type="fig"}). Furthermore, significantly decreased levels of ESR2 (P=0.0097) and AR (P=0.00029) mRNA were detected in GC specimens compared with adjacent healthy controls ([Fig. 1B](#f1-ol-0-0-5881){ref-type="fig"}). Amongst the steroid hormone receptors investigated, the expression levels of ESR2 and AR mRNA were the highest, with expression of ESR1 mRNA low in tumoral and adjacent healthy gastric tissue samples (data not shown). Amongst the coregulators of steroid hormones receptors examined, the expression of NCOA1 (P=0.00021) and NCOR1 (P=0.00017) mRNA was significantly reduced in tumoral mucosa compared with adjacent healthy mucosa ([Fig. 1C](#f1-ol-0-0-5881){ref-type="fig"}). In addition, no significant differences were observed in the expression of PELP1 (P=0.19), CREBBP (P=0.06) and NR2F1 (P=0.11) mRNA between tumoral and healthy tissue samples ([Fig. 1C](#f1-ol-0-0-5881){ref-type="fig"}).

### Analysis of the clinicopathological characteristics of patients with GC and mRNA levels of STS, HSD3B1, CYP19, ESR2, AR, NCOA1 and NCOR1

Decreased expression of STS, HSD3B1, ESR2, AR, NCOA1 and NCOR1 mRNA, and increased expression of CYP19A1 mRNA in tumoral tissue samples compared with healthy controls, were associated with certain clinicopathological features of patients with GC ([Table III](#tIII-ol-0-0-5881){ref-type="table"}). Expression of STS (P\<0.00001), ESR2 (P=0.0024), AR (P=0.0001), NCOA1 (P=0.00028) and NCOR1 (P=0.00067) mRNA were significantly lower in tumoral tissue samples compared with the control in patients \>60 years. Furthermore, males had significantly lower levels of AR (P=0.0018), NCOA1 (P=0.00051) and NCOR1 (P=0.000095) mRNA in tumoral tissue samples compared with control tissue samples, whereas in females the mRNA level of HSD3B1 was significantly lower in tumoral compared with control tissue samples (P=0.004).

The multisite localization of GC was demonstrated to be associated with a significantly lower level of HSD3B1 mRNA (P=0.0034) and tumors located in the cardia region had significantly lower STS (P=0.0012), AR (P=0.0012), NCOA1 (P=0.001) and NCOR1 (P=0.0073) mRNA, compared with healthy mucosa. However, only 10 patients with tumor localization in the cardia region were included in the analysis. Patients with the intestinal type of GC had significantly lower mRNA levels of AR (P=0.000046) and NCOA1 (P=0.0007) in tumoral tissue samples compared with the control mucosa. In addition, significantly lower levels of STS mRNA were identified in tumoral tissue compared with adjacent healthy tissue in patients with indeterminate GC (P=0.0032). Additionally, cancerous tissue samples of a T3 grade expressed significantly lower levels of STS (P=0.00018) and HSD3B1 (P=0.0062) mRNA compared with healthy tissue samples. A significantly lower level of AR mRNA was also identified in tumoral tissue graded as T4 compared with the control (P=0.0086). Expression of STS mRNA was significantly decreased in the tumoral tissue samples of patients with N3 lymph node metastases compared with the controls samples (P=0.000089).

The majority of patients were diagnosed with an M0 metastasis stage, thus no associations between the mRNA levels of the analyzed genes and metastasis grade were investigated. Significantly lower levels of AR (P=0.00062) and NCOA1 (P=0.0027) mRNA were identified in the tumoral tissue of patients with G2 stage GC compared with adjacent healthy tissue. In addition, STS (P=0.000054) and HSD3B1 (P=0.0012) mRNA expression was significantly lower in G3 histological grade tumors compared with healthy tissue samples. However, the expression of CYP19A1 mRNA was significantly increased in tumoral tissue samples compared with the control in patients with multisite localization of GC (P=0.00001), a T3 tumor stage (P=0.00001), N0 (P=0.0024) or N3 (P=0.001) lymph node metastasis grades and G3 histological grade tumors (P\<0.00001). The expression of CYP19A1 mRNA in primary tumoral tissue samples compared with healthy adjacent mucosa samples was significantly increased in all patients studied, regardless of age, gender, and histological type and localization of the tumor.

Discussion
==========

In the present study, the mRNA levels of specific genes involved in the synthesis of E2, in addition to genes encoding steroid hormone receptors and their coregulators, were investigated in primary tumoral and adjacent healthy gastric mucosa samples obtained from patients with GC. The presence of mRNA was detected for all genes analyzed in the majority of gastric specimens examined. Furthermore, it was identified that the expression of STS, HSD3B1, ESR2, AR, NCOA1 and NCOR1 mRNA was significantly decreased, whereas, the level of CYP19A1 mRNA was significantly increased, in cancerous gastric tissue compared with the control samples. To the best of our knowledge, no previous studies have investigated the expression of STS, HSD3B1 and NCOA1 mRNA in patients with GC, although their association with other tumor types has been examined.

Previous studies have identified lower levels of STS mRNA in primary colorectal adenocarcinoma compared with adjacent healthy colon mucosa ([@b23-ol-0-0-5881]). This is consistent with the results of the present study, which identified significantly decreased levels of STS mRNA in tumoral compared with healthy gastric tissue. As E1 and DHEA are typically found in their inactive sulfated form in the blood and have to undergo STS-mediated activation prior to entering the steroidogenesis pathway ([@b24-ol-0-0-5881],[@b25-ol-0-0-5881]), downregulation of STS in a particular tissue may suppress the synthesis of estrogens and androgens ([@b26-ol-0-0-5881]). By contrast, higher levels of E2 have been identified in cancerous tissue compared with healthy tissue in patients with breast cancer ([@b26-ol-0-0-5881],[@b27-ol-0-0-5881]). In addition, numerous studies have reported an increase in the activity and expression of STS in breast cancer ([@b28-ol-0-0-5881]--[@b33-ol-0-0-5881]). Therefore, it has been suggested that upregulation of STS may be associated with higher concentrations of intratumoral E2 ([@b28-ol-0-0-5881],[@b30-ol-0-0-5881],[@b32-ol-0-0-5881]).

Desulfated DHEA that is converted into adione, typically by HSD3B1, may serve as a substrate of E2 synthesis through the aromatase signaling pathway ([@b25-ol-0-0-5881]). However, low expression of HSD3B1 mRNA was observed in tumoral and healthy gastric tissue samples, with expression lower in the tumoral mucosa compared with the adjacent healthy tissue. Conversely to the results of the present study, increased expression of HSD3B1 mRNA has been identified in benign prostatic hyperplasia compared with healthy adjacent prostate tissue samples ([@b34-ol-0-0-5881]), in addition to castration-resistant metastases compared with primary prostate tumors ([@b35-ol-0-0-5881]). HSD3B1 activity is essential for the production of adione, which is subsequently used as a substrate for the synthesis of testosterone, an important hormone that regulates the proliferation of prostate cells ([@b36-ol-0-0-5881]). Furthermore, adione and testosterone can be directly converted to E1 and E2, respectively, by CYP19A1 ([@b25-ol-0-0-5881]). In the current study, expression of CYP19A1 mRNA was demonstrated in the majority of healthy gastric tissue samples and all tumoral gastric tissue samples. A previous study identified the presence of CYP19A1 in 23/30 GC tissue samples; however, all healthy gastric mucosa specimens tested negative for this enzyme ([@b37-ol-0-0-5881]). The presence of CYP19A1 mRNA and protein has been revealed in healthy and tumoral gastric tissue samples, although no significant difference in the level of CYP19A1 mRNA was demonstrated between healthy and tumoral gastric tissue samples ([@b38-ol-0-0-5881]). These findings oppose the results of the present study; however, this may have been due to the fact that the previous study analyzed a total of five cases ([@b38-ol-0-0-5881]).

Numerous animal studies have demonstrated that parietal cells are capable of converting circulating androgens into estrogens, whilst simultaneously expressing CYP19A1 ([@b39-ol-0-0-5881]--[@b44-ol-0-0-5881]). Furthermore, the synthesis of E2 through the aromatization of exogenous testosterone has been demonstrated in various GC cell lines ([@b38-ol-0-0-5881]). Considering these findings and the numerous evidence for the protective role of E2 against GC ([@b6-ol-0-0-5881]--[@b12-ol-0-0-5881]), the increased level of CYP19A1 mRNA in tumoral tissue samples compared with the control group observed in the present study is difficult to explain. However, it was observed that the expression of CYP19A1 mRNA in cancerous and healthy tissues was maintained at a low level, indicating that the role CYP19A1 serves in estrogen synthesis in gastric tissue may be limited. Additionally, it has been demonstrated that E2 may inhibit CYP19A1 and STS activity in breast cancer cells ([@b45-ol-0-0-5881],[@b46-ol-0-0-5881]), suggesting that the increased mRNA expression of CYP19A1 in GC could be due to lower intracellular concentrations of E2.

Cellular responses to steroid hormones are facilitated by steroid hormones binding to their receptors, such as ESR1, ESR2 and AR ([@b47-ol-0-0-5881]). Studies that investigated the association between these receptors and GC have produced inconsistent results ([@b18-ol-0-0-5881],[@b19-ol-0-0-5881],[@b48-ol-0-0-5881]). ESR1 has been suggested to mediate the cancer-promoting effects of E2 in breast ([@b49-ol-0-0-5881],[@b50-ol-0-0-5881]), colon ([@b51-ol-0-0-5881]), prostate ([@b52-ol-0-0-5881]) and gastric ([@b53-ol-0-0-5881]--[@b57-ol-0-0-5881]) cells, whereas binding of E2 to ESR2 could inhibit cell proliferation in tumors of these tissues ([@b51-ol-0-0-5881],[@b53-ol-0-0-5881],[@b55-ol-0-0-5881],[@b57-ol-0-0-5881]--[@b61-ol-0-0-5881]). In the current study, no significant difference in the expression of ESR1 mRNA was identified between healthy and tumoral gastric tissue samples; however, the expression of ESR2 mRNA was significantly lower in cancerous mucosa compared with the control. Thus, the results of the present study support the hypothesis that reduced ESR2 expression is associated with the development of GC. Conversely, Matsuyama *et al* ([@b62-ol-0-0-5881]) suggested that the role served by ESR2 in GC may differ depending on the subtype. Furthermore, Guo *et al* ([@b63-ol-0-0-5881]) demonstrated that certain splicing variants of ESR2 mRNA (ESR2-1, −2 and −5) are differentially expressed in GC and healthy tissue samples. Additionally, higher levels of ESR2-5 mRNA were detected in GC compared with healthy tissue samples, and were associated with tumor-node-metastasis (TNM) staging, while decreased mRNA levels of ESR2-1 in GC did not correlate with any clinicopathological characteristics. In the current study, patients who were \>60 years old had significantly lower levels of ESR2 mRNA in tumoral compared with healthy gastric tissue samples; however, all ESR2 splicing variants were analyzed simultaneously. A previous study suggested that ESR1 may exhibit antiproliferative activity, and reduce the motility and invasion of GC cells ([@b64-ol-0-0-5881]). Furthermore, ESR1 has been associated with an early TNM stage in GC ([@b18-ol-0-0-5881]). Thus, further studies investigating the role of ESRs in the etiology of GC are warranted.

In addition to investigating ESRs, the expression of AR mRNA was investigated in the current study. Previous studies have proposed that AR expression is an unfavorable factor in GC ([@b19-ol-0-0-5881],[@b65-ol-0-0-5881],[@b66-ol-0-0-5881]). In the present study, it was demonstrated that expression of AR mRNA was significantly decreased in GC tissue compared with controls. Similarly, decreased mRNA expression of AR in GC tissue samples has been reported by Gan *et al* ([@b18-ol-0-0-5881]). Low expression of AR and ESR1 mRNA was observed in cancerous and wild-type gastric mucosa, whereas the ESR2 mRNA was predominantly expressed in the both of these tissues. However, the expression of AR and ESR2 mRNA in GC tissue samples and matched controls was the highest amongst the analyzed steroid hormone receptors in the present study. The STS substrates E1-S and DHEA-S have been demonstrated to induce transactivation of ESRs and AR in a concentration-dependent manner in the MVLN invasive ductal carcinoma and CHO-K1 ovarian cell lines, respectively ([@b67-ol-0-0-5881]). The results of the current study suggest that DHEA-S is hydrolyzed by STS prior to AR activation, whereas E1-S may be active prior to STS-mediated hydrolysis. Thus, the decreased expression of AR mRNA in GC may have been due to reduced androgen synthesis caused by STS downregulation. Notably, decreased expression of HSD3B1 mRNA, which is essential for androgen synthesis from DHEA, was detected in the present study.

The activity of nuclear steroid hormone receptors is regulated by various coactivators and corepressors ([@b68-ol-0-0-5881]). In the current study, NCOR1 and NCOA1 were demonstrated to be downregulated in GC tissue samples compared with healthy controls. Furthermore, mRNA and protein expression of NCOR1 has been identified to be downregulated in gastrointestinal stromal tumors, where it has been proposed to serve as a tumor suppressor through the SMAD signaling pathway ([@b69-ol-0-0-5881]). In contrast to these findings, another study identified increased mRNA expression of NCOR1 in malignant endometrial tissue samples compared with healthy tissue samples ([@b70-ol-0-0-5881]). Furthermore, high mRNA expression of NCOR1 has been associated with the improved prognosis of patients with breast cancer ([@b71-ol-0-0-5881]), whereas a loss of nuclear NCOR1 has been revealed to cause increased expression of cancer-associated genes and be significantly associated with the progression of invasive malignant melanoma ([@b72-ol-0-0-5881]). Upregulation of NCOR1 mRNA and protein expression, induced by progestins, has been associated with the suppression of estrogen-induced growth in T47D breast cancer cells ([@b73-ol-0-0-5881]).

In the present study, it was demonstrated that expression of NCOA1 mRNA was reduced in tumoral compared with healthy gastric tissue samples. Similarly, downregulation of NCOA1 mRNA has been identified in cancerous bladder urothelium samples ([@b74-ol-0-0-5881]). Additionally, high mRNA levels of NCOA1 have been observed in healthy breast tissue samples, intermediate levels in tumoral tissue samples and low levels in breast cancer cell lines ([@b75-ol-0-0-5881]). However, numerous studies have identified an association between increased expression of NCOA1 and enhanced angiogenesis, cell proliferation and survival, disease recurrence, higher tumor grade and poor prognosis in breast cancer ([@b76-ol-0-0-5881]--[@b81-ol-0-0-5881]). Notably, upregulation of NCOA1 has been observed in patients with breast cancer treated with aromatase inhibitors ([@b82-ol-0-0-5881]). Thus, the decreased levels of NCOA1 mRNA in GC tissue identified in the present study may have been due to upregulation of CYP19A1 mRNA in tumoral gastric mucosa. Tai *et al* ([@b83-ol-0-0-5881]) demonstrated that overexpression of NCOA1 enhanced the E2-induced growth of MCF-7 breast cancer cells. Increased expression of NCOA1 has also been associated with the DHEA-mediated activation of AR in prostate cancer ([@b84-ol-0-0-5881]). Therefore, the decreased expression of AR and NCOA1 mRNA that were observed in cancerous gastric tissue samples in the present study may have been the result of limited desulfation of DHEA-S due to the downregulation of STS.

In conclusion, the presence of STS, HSD3B1, CYP19A1, HSD17B7, ESR1, ESR2, AR, PELP1, CREBBP, NCOA1, NCOR1 and NR2F1 mRNA was demonstrated in the majority of tumoral and adjacent healthy gastric mucosa tissue samples. Furthermore, significantly decreased mRNA levels of STS and HSD3B1, in addition to significantly increased expression levels of CYP19A1 mRNA, in tumoral gastric tissue samples compared with matched controls were identified. However, compared with STS, the expression of HSD3B1 and CYP19A1 mRNA was low in the majority of the examined tissue samples, indicating that their role in gastric carcinogenesis is limited. Additionally, tumoral gastric tissue samples exhibited decreased levels of NCOA1 and NCOR1 mRNA compared with adjacent healthy controls, suggesting that deregulated expression of these coregulators may serve a role in gastric carcinogenesis. A limitation of the current study was the use of homogenized tissue samples, and thus the possibility that the samples included non-cancerous cells, such as fibroblasts, endothelial cells, smooth muscle cells or blood cells, could not be excluded. Furthermore, mRNA abundance does not always correlate with protein expression. Therefore, further studies on the expression levels of the genes involved in the steroidogenesis pathway and their role in gastric carcinogenesis are warranted.
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![Relative expression of STS, HSD3B1, CYP19A1, HSD17B7, ESR1, ESR2, AR, PELP1, CREBBP, NCOA1, NCOR1 and NR2F1 mRNA in healthy and primary tumoral gastric tissue samples. (A) Expression of genes encoding steroidogenic enzymes. (B) Expression levels of genes encoding steroid hormone receptors. (C) Expression of genes encoding coregulators of steroid hormone receptors. White dots represent healthy tissue and black dots represent primary tumoral tissue from patients with gastric cancer, which were analyzed through reverse transcription-quantitative polymerase chain reaction analysis and normalized to expression levels of β2-microglobulin, β-glucuronidase and porphobilinogen deaminase. The quantity of analyzed genes is presented as the decimal logarithm that represents the ratio between the amount of target gene in a sample and the target gene in the calibrator. STS, steroid sulfatase; HSD3B1, hydroxy-delta-5-steroid dehydrogenase 3 beta- and steroid delta-isomerase 1; CYP19A1, aromatase; HSD17B7, 17β-hydroxysteroid dehydrogenase type 7; ESR1, estrogen receptor α; ESR2, estrogen receptor β; AR, androgen receptor; PELP1, proline, glutamate and leucine rich protein 1; CREBBP, CREB binding protein; NCOA1, nuclear receptor coactivator 1; NCOR1, nuclear receptor corepressor 1; NR2F1, nuclear receptor subfamily 2, group F, member 1.](ol-13-05-3369-g00){#f1-ol-0-0-5881}

###### 

Available clinicopathological characteristics of patients with gastric cancer.

  Clinicopathological characteristic   No. of patients
  ------------------------------------ -----------------
  Gender (male/female)                 36/24
  GC localization                      
    Multisite                          31
    Cardia                             10
    Trunk                                6
    Fundus                               1
    Lesser curvature                     5
    Pylorus                              3
  Histological type                    
    Diffuse                            19
    Intestinal                         23
    Undetermined                       12
  Tumor stage                          
    T1                                   2
    T2                                   9
    T3                                 32
    T4                                 15
  Lymph node metastasis stage          
    N0                                 17
    N1                                 8
    N2                                 14
    N3                                 19
  Metastasis stage                     
    M0                                 45
    M1                                   3
  Histological grading                 
    G1                                   1
    G2                                 17
    G3                                 38

T, tumor; N, node; M, metastasis, G, grade.

###### 

Primer sequences and qPCR conditions.

  Gene      Sequence (5′-3′)         Exon number        Product size (bp)   qPCR thermocycling conditions (denaturation; annealing; elongation)
  --------- ------------------------ ------------------ ------------------- ---------------------------------------------------------------------
  STS       GCCAGAAGATTGATGAGCCCAC   ENSE00001203198    174                 95°C/8 sec;
            AGGCGTTGCAGTAATGGAAGAG   ENSE00001136339                        62°C/8 sec;
                                                                            72°C/8 sec
  HSD3B1    GATGTCTTCGGTGTCACTCA     ENSE00001722296    129                 95°C/8 sec;
            GGCTACCTCTATGCTACTG      ENSE00001846945                        57°C/8 sec;
                                                                            72°C/8 sec
  CYP19A1   CAAACCCAATGAATTTACTCT    ENSE00003683464    111                 95°C/6 sec;
            ACCATGGCGATGTACTTTCC     ENSE00001524808                        58°C/6 sec;
                                                                            72°C/6 sec
  AR        GATCCTTCACCAATGTCAACT    ENSE00001282597    109                 95°C/10 sec;
            CTCATTCGGACACACTGGCT     ENSE00001165458                        60°C/10 sec;
                                                                            72°C/10 sec
  PELP1     GAGCATTCAGCAGGTGTTAC     ENSE00003644127    132                 95°C/10 sec;
            AGGTGGTTCATGGAGATGTC     ENSE00003476735                        60°C/10 sec;
                                                                            72°C/10 sec
  CREBBP    TCTTCCATTGCCACCCACCT     ENSE00003665970    142                 95°C/10 sec;
            CTGTCTTCAGTTGCTTGTTTG    ENSE00003538086                        60°C/10 sec;
                                                                            72°C/10 sec
  NCOA1     GCTGGTATCCTTCCTTAGTG     ENSE00000808889    136                 95°C/10 sec;
            TGGCGTTGCTTGTTGTGGTG     ENSE00000808890                        60°C/10 sec;
                                                                            72°C/10 sec
  NCOR1     GCGTTATGATCAGCTCATGG     ENSE00003681554    202                 95°C/10 sec;
            ACTCCTAGCAATGGTGGCTG     ENSE00003668751                        62°C/10 sec;
                                                                            72°C/10 sec
  NR2F1     CGCATCTTCCAGGAGCAGGT     ENSE00001249995    226                 95°C/6 sec;
            GCAGTCGCAGCAGCAGTTTG     ENSE00001250004                        60°C/6 sec;
                                                                            72°C/6 sec
  GUSB      CGCCGACTTCTCTGACAAC      ENSE00001799401    174                 95°C/10 sec;
            ATCACCTCCCGTTCGTACC      ENSE00003687473                        60°C/10 sec;
                                                                            72°C/10 sec
  PBGD      GCCAAGGACCAGGACATC       ENSE00003460195    160                 95°C/10 sec;
            TCAGGTACAGTTGCCCATC      ENSE00003609229/                       60°C/10 sec;
                                     ENSE00003610664                        72°C/10 sec
  B2M       CACCCCCACTGAAAAAGATG     ENSE00003659794    106                 95°C/10 sec;
            CCTCCATGATGCTGCTTACA     ENSE00003459883/                       60°C/10 sec;
                                     ENSE00002538889                        72°C/10 sec

qPCR, quantitative polymerase chain reaction; STS, steroid sulfatase; HSD3B1, hydroxy-delta-5-steroid dehydrogenase 3 beta- and steroid delta-isomerase 1; CYP19A1, aromatase; AR, androgen receptor; PELP1, proline, glutamate and leucine rich protein 1; CREBBP, CREB binding protein; NCOA1, nuclear receptor coactivator 1; NCOR1, nuclear receptor corepressor 1; NR2F1, nuclear receptor subfamily 2, group F, member 1; GUSB, β-glucuronidase; PBGD, porphobilinogen deaminase; B2M, β2-microglobulin.

###### 

Association between the expression of STS, HSD3B1, CYP19, ESR2, AR, NCOA1 and NCOR1 mRNA in tumoral and healthy gastric tissue samples and the clinicopathological characteristics of patients with GC.

                                Gene analyzed (P-value, GC vs. control tissue)                                                      
  ----------------------------- ------------------------------------------------ -------- ----------- -------- ---------- --------- ----------
  All patients                  \<0.00001                                        0.0051   \<0.00001   0.0097   0.00029    0.00021   0.00017
  Age (years old)                                                                                                                   
    ≤60                         0.9                                              0.2      0.00074     0.89     0.35       0.27      0.22
    \>60                        \<0.00001                                        0.02     0.000012    0.0024   0.0001     0.00028   0.00067
  Gender                                                                                                                            
    Male                        0.0014                                           0.28     0.000072    0.08     0.0018     0.00051   0.000095
    Female                      0.000069                                         0.004    0.00023     0.056    0.04       0.11      0.48
  GC localization                                                                                                                   
    Multisite                   0.013                                            0.0034   0.00001     0.04     0.026      0.12      0.11
    Cardia                      0.0012                                           0.57     0.054       0.55     0.0012     0.001     0.0073
    Body                        --                                               --       --          --       --         --        --
    Fundus                      --                                               --       --          --       --         --        --
    Lesser curvature            --                                               --       --          --       --         --        --
    Pylorus                     --                                               --       --          --       --         --        --
  Histological type                                                                                                                 
    Diffuse                     0.034                                            0.034    0.0018      0.73     0.69       0.36      0.038
    Intestinal                  0.037                                            0.022    0.0074      0.022    0.000046   0.0007    0.019
    Indeterminate               0.0032                                           0.14     0.0009      0.047    0.47       0.71      0.98
  Tumor stage                                                                                                                       
    T1                          --                                               --       --          --       --         --        --
    T2                          0.57                                             0.96     0.11        0.79     0.19       0.093     0.077
    T3                          0.00018                                          0.0062   0.00001     0.022    0.027      0.016     0.038
    T4                          0.014                                            0.11     0.089       0.14     0.0086     0.046     0.074
  Lymph node metastasis stage                                                                                                       
    N0                          0.17                                             0.11     0.0024      0.29     0.16       0.039     0.027
    N1                          0.18                                             0.27     0.052       0.76     0.035      0.014     0.024
    N2                          0.019                                            0.49     0.041       0.22     0.38       0.48      0.53
    N3                          0.000089                                         0.06     0.001       0.045    0.048      0.062     0.21
  Metastasis stage                                                                                                                  
    M0                          0.0021                                           0.003    \<0.00001   0.014    0.00064    0.0028    0.0018
    M1                          --                                               --       --          --       --         --        --
  Histological grading                                                                                                              
    G1                          --                                               --       --          --       --         --        --
    G2                          0.07                                             0.07     0.036       0.24     0.00062    0.0027    0.042
    G3                          0.000054                                         0.0012   \<0.00001   0.027    0.044      0.021     0.0049

Two-tailed Student\'s t-test

Mann-Whitney U test. GC, gastric cancer; STS, steroid sulfatase; HSD3B1, hydroxy-delta-5-steroid dehydrogenase 3 beta- and steroid delta-isomerase 1; CYP19A1, aromatase; ESR2, estrogen receptor β; AR, androgen receptor; NCOA1, nuclear receptor coactivator 1; NCOR1, nuclear receptor corepressor 1; T, tumor; N, node; M, metastasis; G, grade; ↓/↑, down/up-regulation in gastric cancer in compare to healthy controls.
